title: Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, with the greatest challenge for improving patient survival being the management of chemorefractory disease upon relapse. Epigenetic dysregulation has been correlated with more-aggressive malignancies and chemoresistance. In this issue of Cancer Discovery, Clozel and colleagues show the potential for low-dose DNA methyltransferase inhibitors as both a rational and an effective neoadjuvant approach for chemosensitization in DLBCL.
authors.affiliation: 1Marlene & Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland; and 2Veterans Administration Medical Center, Baltimore, Maryland.
authors.forename: James J
authors.initials: JJ
authors.lastname: Steinhardt
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Gartenhaus
mesh_terms: D001374:Azacitidine / Q000627:therapeutic use*; D019175:DNA Methylation / Q000235:genetics*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D015254:DNA Modification Methylases; D001374:Azacitidine
references.citation: Oncogene. 2001 Jul 19;20(32):4383-92
references.pmid: 11466619
references.citation: Haematologica. 2013 Dec;98(12):1912-20
references.pmid: 23831920
references.citation: Blood. 2011 Sep 29;118(13):3559-69
references.pmid: 21828137
references.citation: Br J Cancer. 2001 Oct 19;85(8):1168-74
references.pmid: 11710831
references.citation: Cancer Discov. 2013 Sep;3(9):1002-19
references.pmid: 23955273
references.citation: Leukemia. 2004 Dec;18(12):2015-25
references.pmid: 15470494
references.citation: Aging Cell. 2011 Dec;10(6):949-61
references.pmid: 21824272
references.citation: Oncogene. 2010 Aug 26;29(34):4741-51
references.pmid: 20531305
references.citation: Curr Top Dev Biol. 2013;104:47-83
references.pmid: 23587238
references.citation: J Clin Invest. 2010 Dec 1;120(12):4569-82
references.pmid: 21041953
references.citation: Nature. 2012 Dec 6;492(7427):108-12
references.pmid: 23051747
references.citation: Pharmaceuticals (Basel). 2010 Aug 1;3(8):2411-2469
references.pmid: 21151768
references.citation: Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99
references.pmid: 12769777
references.citation: Oncogene. 2013 Sep 19;32(38):4586-92
references.pmid: 23128397